Impact of obstructive airway diseases (OADs) treatments on adult diphtheria-tetanus-pertussis vaccine (dTap)’s immunogenicity and safety
P. Van den Steen (Wavre, Belgium), V. Berlaimont (Wavre, Belgium), B. Cheuvart (Wavre, Belgium), Q. Deraedt (Wavre, Belgium), L. Valdes Verelst (Wavre, Belgium)
Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Van den Steen (Wavre, Belgium), V. Berlaimont (Wavre, Belgium), B. Cheuvart (Wavre, Belgium), Q. Deraedt (Wavre, Belgium), L. Valdes Verelst (Wavre, Belgium). Impact of obstructive airway diseases (OADs) treatments on adult diphtheria-tetanus-pertussis vaccine (dTap)’s immunogenicity and safety. 3199
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|